Tuberculous Meningitis
Tuberculous meningitis (TBM) is the most severe form of tuberculosis, carrying a mortality rate of 20–50% even with appropriate treatment and leaving a substantial proportion of survivors with permanent neurological disability. TBM results from hematogenous dissemination of Mycobacterium tuberculosis to the meninges, with a predilection for the basilar cisterns. The resultant inflammatory exudate produces the classic triad of basilar meningitis with cranial neuropathies, hydrocephalus, and cerebral vasculitis leading to stroke. Diagnosis is challenging because conventional microbiologic tests have limited sensitivity, and delays in treatment are directly associated with worse outcomes. The disease disproportionately affects immunocompromised patients — particularly those with HIV co-infection — as well as immigrants from endemic regions and young children. For the practicing neurologist, a high index of suspicion and familiarity with the characteristic clinical, laboratory, and imaging findings are essential to initiating timely empiric therapy.
Bottom Line
- High mortality: Even with optimal treatment, TBM carries 20–50% mortality; survivors frequently have permanent deficits including cranial neuropathies, cognitive impairment, and epilepsy
- Classic CSF triad: Lymphocytic pleocytosis, very high protein (>100 mg/dL), and very low glucose — though early disease may show neutrophilic predominance
- Basilar meningitis: Cranial nerve VI is most commonly affected, followed by CN III and CN VII; imaging shows basilar enhancement, hydrocephalus, and tuberculomas
- Start treatment empirically: Do not wait for culture confirmation (takes 2–6 weeks); GeneXpert MTB/RIF provides rapid results (sensitivity 60–80%)
- Adjunctive dexamethasone: Reduces mortality in MRC Stage II and III disease (Thwaites et al., NEJM 2004); taper over 6–8 weeks
- Stroke from vasculitis: Inflammation of basal perforating arteries causes infarcts in the basal ganglia, internal capsule, and thalamus — a hallmark of TBM
- Paradoxical reaction (TB-IRIS): Clinical worsening after treatment initiation, especially in HIV co-infected patients starting antiretroviral therapy; managed with corticosteroids
Epidemiology and Risk Factors
TBM accounts for approximately 1–5% of all tuberculosis cases worldwide, but it is responsible for a disproportionate share of TB-related morbidity and mortality. Globally, approximately 100,000 new cases of TBM occur annually, with the highest burden in sub-Saharan Africa and Southeast Asia.
Risk Factors
Key Risk Factors for TBM
- HIV co-infection: The single greatest risk factor; HIV-positive individuals have 20–30 times the risk of developing TBM compared to HIV-negative populations; TBM occurs at any CD4 count but risk increases markedly when CD4 <200 cells/μL
- Immunosuppression: TNF-α inhibitors, organ transplant recipients, chronic corticosteroid use, diabetes mellitus, malignancy, malnutrition
- Age: Bimodal distribution with peaks in young children (<5 years) and older adults
- Geographic origin: Immigrants from endemic regions (South Asia, sub-Saharan Africa, Southeast Asia, Latin America)
- Close contact: Household contacts of active pulmonary TB cases
- Substance use: Alcohol use disorder and injection drug use are independent risk factors
Pathophysiology
The pathogenesis of TBM is a two-stage process. Primary pulmonary infection leads to hematogenous dissemination, during which bacilli seed the meninges and brain parenchyma, forming small subpial or subependymal foci known as Rich foci. These remain dormant until rupture into the subarachnoid space triggers a vigorous granulomatous inflammatory response.
The basilar cisterns are preferentially affected due to the slow flow of CSF in these dependent regions. The thick, gelatinous exudate that accumulates in the basal cisterns is responsible for the three cardinal pathological processes of TBM:
| Pathological Process | Mechanism | Clinical Manifestation |
|---|---|---|
| Basilar meningitis | Granulomatous exudate encasing cranial nerves at the skull base | Cranial neuropathies (CN VI, III, VII most common) |
| Hydrocephalus | Obstruction of CSF flow at basal cisterns (communicating) or aqueduct (obstructive) | Headache, papilledema, altered consciousness, gait disturbance |
| Vasculitis | Inflammation of perforating arteries of the circle of Willis and basal perforators | Ischemic stroke — basal ganglia, internal capsule, thalamus, brainstem |
| Tuberculomas | Coalescence of granulomas in brain parenchyma | Mass effect, seizures, focal deficits |
Clinical Presentation
TBM classically presents as a subacute to chronic meningitis evolving over days to weeks, distinguishing it from the acute presentation of bacterial meningitis. The prodromal phase, lasting 1–3 weeks, is characterized by malaise, low-grade fever, headache, and personality changes. This is followed by progressive meningeal symptoms and neurological deterioration.
Cardinal Features
Clinical Manifestations of TBM
- Meningeal signs: Headache (often the earliest symptom), neck stiffness, photophobia, vomiting; may be subtle or absent in immunocompromised patients and the elderly
- Cranial neuropathies: Present in 25–50% of cases; CN VI (abducens) is most commonly affected due to its long subarachnoid course, followed by CN III and CN VII
- Altered consciousness: Progressive confusion, drowsiness, and eventually coma; correlates with disease stage and hydrocephalus severity
- Seizures: Occur in 20–30% of adults and up to 50% of children; may be focal or generalized
- Focal deficits: Hemiparesis, movement disorders, or aphasia from vasculitic infarction; often involve basal ganglia and internal capsule territories
- Hydrocephalus: Develops in 60–80% of cases; headache, papilledema, downgaze palsy (Parinaud syndrome in aqueductal obstruction)
- Systemic features: Fever (80%), weight loss, night sweats; concurrent pulmonary TB in 30–50% of adults
MRC (British Medical Research Council) Staging
The MRC staging system, first proposed in 1948 and still widely used, provides a standardized assessment of disease severity and is the strongest predictor of outcome in TBM.
| MRC Stage | Definition | GCS | Approximate Mortality | Key Features |
|---|---|---|---|---|
| Stage I | Alert, no focal deficits | 15 | 10–20% | Nonspecific symptoms only; meningismus; no neurological compromise |
| Stage II | Confused or focal deficits | 11–14 | 30–40% | Cranial neuropathies, hemiparesis, or lethargy; the critical window for intervention |
| Stage III | Comatose or dense deficit | <11 | 50–70% | Decerebrate or decorticate posturing; multiple CN palsies; status epilepticus |
Red Flags for TBM
- Subacute meningitis with cranial neuropathies: Any patient with meningitis evolving over days to weeks with cranial nerve involvement should be evaluated for TBM
- Basilar meningeal enhancement on MRI: This pattern is highly suggestive of TBM and should prompt empiric treatment if clinical suspicion is present
- CSF with very low glucose (<45 mg/dL) and very high protein (>100 mg/dL): While not pathognomonic, this profile in the setting of lymphocytic pleocytosis strongly suggests TBM
- Rapid deterioration in consciousness: Suggests evolving hydrocephalus or vasculitic stroke; urgent imaging is required
- HIV-positive patient with chronic headache and CSF pleocytosis: Always include TBM in the differential alongside cryptococcal meningitis
Diagnosis
Cerebrospinal Fluid Analysis
The CSF profile in TBM is the cornerstone of diagnosis, though no single finding is pathognomonic. The classic pattern is a lymphocytic pleocytosis with markedly elevated protein and depressed glucose. Notably, early TBM may show a neutrophilic predominance that transitions to lymphocytic predominance over days.
| CSF Parameter | Typical TBM Finding | Clinical Notes |
|---|---|---|
| Opening pressure | Elevated (often >25 cm H2O) | May be markedly elevated with hydrocephalus |
| White cell count | 100–500 cells/μL (range 10–1,000) | Lymphocytic predominance; may be neutrophilic in first 48–72 hours |
| Protein | 100–500 mg/dL (often >100) | Among the highest CSF protein levels of any meningitis; may exceed 1,000 mg/dL with spinal block |
| Glucose | Very low (<45 mg/dL); CSF:serum ratio <0.5 | May approach 0 in severe cases; one of the most useful diagnostic clues |
| Appearance | Clear to opalescent | "Fibrin web" or pellicle may form if specimen left standing for 12–24 hours |
Microbiologic and Molecular Testing
| Test | Sensitivity | Specificity | Time to Result | Key Points |
|---|---|---|---|---|
| AFB smear (Ziehl-Neelsen) | 10–20% | >95% | Same day | Low sensitivity; improved by examining large CSF volumes (≥6 mL) and centrifuging |
| Mycobacterial culture | 50–70% | ~100% | 2–6 weeks | Gold standard; allows drug susceptibility testing; do not delay treatment while awaiting results |
| GeneXpert MTB/RIF (Xpert) | 60–80% | >99% | 2 hours | WHO-recommended first test; also detects rifampin resistance; sensitivity improved with larger CSF volume |
| Xpert Ultra | 70–90% | 95–98% | 2 hours | Improved sensitivity over Xpert, particularly in HIV-positive patients; may have slightly lower specificity |
| Adenosine deaminase (ADA) | 70–90% | 80–90% | Same day | ADA >8–10 IU/L supportive; elevated in other conditions (lymphoma, sarcoidosis); lower threshold in HIV-positive |
| Interferon-γ release assays | Variable | Variable | 1–2 days | CSF-based assays under investigation; blood IGRA does not confirm active TBM but supports TB exposure |
Practical Diagnostic Approach
- Collect adequate CSF volume: At least 6–10 mL improves sensitivity of AFB smear, culture, and Xpert
- Send CSF for Xpert Ultra as the first-line rapid test (WHO recommendation since 2017)
- Always send mycobacterial culture for definitive diagnosis and drug susceptibility testing
- Check ADA as an adjunctive marker; particularly useful in resource-limited settings
- Do not delay treatment: If clinical and CSF findings are suggestive, start empiric anti-TB therapy immediately
- Serial lumbar punctures: If initial Xpert is negative but suspicion remains high, repeat LP in 48–72 hours; sensitivity improves with repeated sampling
- Evaluate for concurrent pulmonary TB: Chest X-ray shows active or prior TB in 30–50% of TBM patients
The Lancet Consensus Scoring System
The Lancet consensus scoring system (Marais et al., 2010) provides a standardized approach to classifying TBM as "definite," "probable," or "possible" based on clinical, CSF, neuroimaging, and microbiologic criteria. A score ≥12 without microbiologic confirmation classifies as "probable TBM," while any positive microbiologic result (culture, smear, or Xpert) classifies as "definite TBM."
Neuroimaging
MRI with gadolinium is the imaging modality of choice and is abnormal in the majority of TBM cases. CT with contrast can demonstrate the major findings but is less sensitive, particularly for early parenchymal disease and infarctions.
| Imaging Finding | Frequency | Description | Clinical Correlation |
|---|---|---|---|
| Basilar meningeal enhancement | 60–90% | Thick, nodular enhancement in basal cisterns on post-contrast T1; suprasellar cistern, sylvian fissures, ambient cisterns | Most characteristic imaging finding; cranial neuropathies |
| Hydrocephalus | 60–80% | Usually communicating; ventriculomegaly with transependymal flow | May require emergent CSF diversion; correlates with clinical stage |
| Tuberculomas | 10–30% | Ring-enhancing lesions with central caseation; "target sign" (central calcification with surrounding edema) | May appear or enlarge paradoxically during treatment; mass effect, seizures |
| Infarcts | 20–40% | Basal ganglia, internal capsule, thalamus, caudate; medial striate and thalamoperforating artery territories | Due to vasculitis of perforating arteries; poor prognostic sign |
| Cranial nerve enhancement | Variable | Enhancement of CN III, VI, VII, or optic chiasm | Correlates with clinical cranial neuropathies |
Treatment
Anti-Tuberculous Therapy
The standard treatment regimen for TBM follows a two-phase approach with modifications from pulmonary TB guidelines, primarily in duration and drug selection based on CNS penetration.
| Phase | Duration | Drugs | Key Pharmacologic Notes |
|---|---|---|---|
| Intensive phase | 2 months | Rifampin (R), Isoniazid (H), Pyrazinamide (Z), Ethambutol (E) | Isoniazid and pyrazinamide have excellent CSF penetration; rifampin achieves adequate but lower CSF levels; ethambutol has poor CNS penetration but is included for initial coverage |
| Continuation phase | 7–10 months | Rifampin (R) + Isoniazid (H) | Total treatment duration: 9–12 months (WHO recommends 12 months); some experts advocate extended treatment for complicated cases |
Drug Dosing and Supplementation
- Isoniazid: 5 mg/kg/day (max 300 mg); best CNS penetration of all first-line agents; hepatotoxic
- Rifampin: 10 mg/kg/day (max 600 mg); some experts advocate higher doses (15 mg/kg) for TBM to improve CSF penetration; potent CYP450 inducer with extensive drug interactions
- Pyrazinamide: 25 mg/kg/day; excellent CSF penetration; hepatotoxic; hyperuricemia
- Ethambutol: 15–20 mg/kg/day; poor CSF penetration; optic neuritis risk (monitor visual acuity and color vision)
- Pyridoxine (vitamin B6): 25–50 mg/day with isoniazid to prevent peripheral neuropathy — mandatory supplementation
- Ethionamide or fluoroquinolone: Some experts substitute for ethambutol due to superior CSF penetration, particularly in severe disease
Adjunctive Corticosteroids
The use of adjunctive dexamethasone in TBM is supported by a landmark randomized controlled trial by Thwaites and colleagues, published in the New England Journal of Medicine in 2004. This trial of 545 patients in Vietnam demonstrated a significant reduction in mortality with dexamethasone across all MRC stages, though the benefit was most pronounced in Stage II and III disease.
| MRC Stage | Dexamethasone Dose | Duration | Taper Schedule |
|---|---|---|---|
| Stage I | 0.3 mg/kg/day IV | Weeks 1–2 | Transition to oral at week 3; taper over total 6–8 weeks |
| Stage II–III | 0.4 mg/kg/day IV | Weeks 1–4 | Transition to oral at week 5; taper over total 6–8 weeks |
Important Caveats with Corticosteroids
- Mortality benefit confirmed, but disability outcomes less clear: Dexamethasone reduces death but may not significantly reduce severe disability in survivors
- HIV co-infection: The Thwaites trial included HIV-positive patients, but a subsequent larger trial (ACT HIV, NEJM 2023) showed no mortality benefit of dexamethasone in HIV-associated TBM — this remains an area of active debate
- Drug-resistant TB: The evidence base for corticosteroids in MDR-TBM is limited; use is generally recommended but with close monitoring
- Do not abruptly discontinue: Gradual taper over 6–8 weeks is essential; premature withdrawal may trigger paradoxical worsening
Hydrocephalus Management
Hydrocephalus is present in the majority of TBM patients and is a major determinant of outcome. Most cases represent communicating hydrocephalus due to impaired CSF absorption from basilar exudate, though obstructive hydrocephalus may occur from tuberculoma or aqueductal compression.
Approach to Hydrocephalus in TBM
- Communicating hydrocephalus (most common): May respond to medical therapy (anti-TB drugs + corticosteroids + serial LPs); if progressive or symptomatic, ventriculoperitoneal (VP) shunt is indicated
- Obstructive hydrocephalus: Requires emergent external ventricular drain (EVD) placement; subsequent VP shunt if needed
- Serial lumbar punctures: Can be used as a temporizing measure in communicating hydrocephalus while anti-TB therapy takes effect
- Endoscopic third ventriculostomy (ETV): Increasingly used as an alternative to VP shunt in obstructive cases
- VP shunt complications: Risk of shunt infection, obstruction, and over-drainage; patients require long-term follow-up
Drug-Resistant TBM
Multidrug-resistant (MDR) TBM, defined as resistance to at least rifampin and isoniazid, carries a devastatingly high mortality rate exceeding 80% in some series. The management of MDR-TBM requires individualized regimens based on drug susceptibility results, with an emphasis on agents with adequate CNS penetration.
Approach to Drug-Resistant TBM
- GeneXpert MTB/RIF detects rifampin resistance: Any rifampin resistance on Xpert should prompt immediate consultation with infectious disease and TB specialists
- Fluoroquinolones (moxifloxacin, levofloxacin): Excellent CSF penetration; backbone of MDR-TBM regimens
- Linezolid: Good CSF penetration; important component of MDR regimens; monitor for myelosuppression and peripheral neuropathy with prolonged use
- Cycloserine: Good CSF penetration; neuropsychiatric side effects (seizures, psychosis) limit use
- Duration: Extended treatment (18–24 months or longer) is typically required
- Bedaquiline and delamanid: Newer agents with limited CNS penetration data; role in TBM is evolving
Paradoxical Reaction and TB-IRIS
A paradoxical reaction refers to clinical or radiographic worsening that occurs after initiation of appropriate anti-TB therapy, despite microbiologic improvement. This phenomenon is attributed to an exaggerated immune reconstitution response as the mycobacterial burden decreases and the immune system rebounds. In HIV co-infected patients initiating antiretroviral therapy (ART), this is termed TB-associated immune reconstitution inflammatory syndrome (TB-IRIS).
Paradoxical Reaction in TBM
- Timing: Typically occurs 2–12 weeks after starting anti-TB therapy; in HIV-positive patients, often 1–4 weeks after ART initiation
- Manifestations: New or enlarging tuberculomas, worsening hydrocephalus, new cranial neuropathies, expanding basilar exudate, worsening vasculitis and new infarcts
- Frequency: Occurs in 10–30% of TBM patients; higher in HIV-positive patients starting ART
- Differentiation from treatment failure: Paradoxical reaction occurs in the context of improving CSF parameters and declining mycobacterial burden; treatment failure shows persistent or worsening CSF and positive cultures
- Management: Corticosteroids (dexamethasone or prednisone) are the mainstay; do not discontinue anti-TB therapy; may require prolonged steroid courses
- ART timing in HIV-TBM: Delay ART initiation for 2–8 weeks after starting anti-TB therapy to reduce IRIS risk (WHO recommendation)
Special Populations
HIV Co-Infection
TBM in HIV-positive patients presents unique diagnostic and therapeutic challenges. CSF findings may be atypical — with lower white cell counts, less protein elevation, and fewer classic imaging features — due to impaired immune responses. Drug interactions between rifampin and antiretroviral agents (particularly protease inhibitors and some integrase inhibitors) complicate management. The optimal timing of ART initiation remains a critical question; current guidelines recommend delaying ART for 2–8 weeks after starting anti-TB therapy.
Pediatric TBM
Children under 5 years are at highest risk for progression from primary infection to TBM. Presentation may be nonspecific, with irritability, poor feeding, and developmental regression. Seizures are more common in children than adults. BCG vaccination does not reliably prevent TBM but may reduce the risk of disseminated TB in young children.
Prognosis
| Prognostic Factor | Better Outcome | Worse Outcome |
|---|---|---|
| MRC stage at presentation | Stage I | Stage III |
| HIV status | HIV-negative | HIV-positive (especially low CD4) |
| Time to treatment | Early empiric therapy | Delayed treatment (>5 days from presentation) |
| Drug resistance | Drug-susceptible TB | MDR or XDR-TB |
| Stroke | No infarcts | Vasculitic infarction at presentation |
| Hydrocephalus | Absent or responsive to treatment | Refractory hydrocephalus requiring shunting |
| Age | Younger adults | Extremes of age (very young children, elderly) |
Long-term sequelae in survivors include cognitive impairment (30–50%), epilepsy (20–30%), persistent cranial neuropathies (15–25%), motor deficits from stroke, and shunt-dependent hydrocephalus. Neuropsychological follow-up is recommended for all TBM survivors.
References
- Thwaites GE, van Toorn R, Schoeman J. Tuberculous meningitis: more questions, still too few answers. Lancet Neurol. 2013;12(10):999–1010.
- Thwaites GE, Nguyen DB, Nguyen HD, et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med. 2004;351(17):1741–1751.
- Marais S, Thwaites G, Schoeman JF, et al. Tuberculous meningitis: a uniform case definition for use in clinical research. Lancet Infect Dis. 2010;10(11):803–812.
- Donovan J, Thwaites GE, Huynh J. Tuberculous meningitis: where to from here? Curr Opin Infect Dis. 2020;33(3):259–266.
- Wilkinson RJ, Rohlwink U, Misra UK, et al. Tuberculous meningitis. Nat Rev Neurol. 2017;13(10):581–598.
- Stadelman AM, Ellis J, Samuels THA, et al. Treatment outcomes in adult tuberculous meningitis: a systematic review and meta-analysis. BMC Infect Dis. 2020;20(1):793.
- Donovan J, Phu NH, Thao LTP, et al. Adjunctive dexamethasone for tuberculous meningitis in HIV-positive adults (ACT HIV). N Engl J Med. 2023;389(15):1357–1367.
- Cresswell FV, Te Brake L,";";"; et al. Intensified antibiotic treatment of tuberculous meningitis. Expert Rev Clin Pharmacol. 2019;12(8):789–800.
- World Health Organization. WHO consolidated guidelines on tuberculosis. Module 1: prevention – tuberculosis preventive treatment. Geneva: WHO; 2020.
- Tuberculous Meningitis International Research Consortium. Uniform clinical case definition for tuberculous meningitis. Lancet Infect Dis. 2010;10(11):803–812.
- Seddon JA, Wilkinson RJ, van Crevel R, et al. Knowledge gaps and research priorities in tuberculous meningitis. Wellcome Open Res. 2019;4:188.
- Bahr NC, Boulware DR. Methods of rapid diagnosis for the etiology of meningitis in adults. Biomark Med. 2014;8(9):1085–1103.